• Source: Scopus
19952020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

My collaborators and I have studied adverse events in the atrial fibrillation population. We developed clinical prediction rules for stroke (“CHADS2”) and for bleeding (“HEMORR2HAGES”) in the atrial fibrillation population. We have quantified the costs, risks, and benefits of warfarin therapy and newer anticoagulants. We use pharmacogenetics to improve the safety and effectiveness of warfarin. We have collaborated with geneticists to discover new polymorphisms that predict warfarin sensitivity. We are also studying how physicians should use this genetic information and have developed a non-profit website, www.WarfarinDosing.org. We are using this site to clarify determinants of warfarin dose and to test the hypothesis that clinicians can estimate a safe warfarin dose a priori, rather than by using the current trial-and-error warfarin dosing.

Areas of Clinical Interest

CURRENTLY ACCEPTING PHYSICIAN REFERRALS AND PHYSICIAN CONSULTATION ONLYGeneral internal medicine, anti-coagulation, antithrombolic therapy, deep venous thrombosis, blood thinners, aspirin, Warfarin, Coumadin, stroke prevention.See News Article on Stroke Prevention using blood thinners.

Fingerprint

Dive into the research topics where Brian Gage is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 3 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.
If you made any changes in Pure these will be visible here soon.